Anti-yellow fever virus antibodies, and methods of their generation and use
AssigneeMabloc, Inc.
InventorsAnna Wec, Laura Walker
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen-binding fragments thereof specific to the YFV E protein and with neutralizing potency against YFV are provided. These antibodies and antigen-binding fragments are useful in treating YFV.
Claims17
A method of treating or preventing a Yellow Fever Virus (YFV) infection or at least one symptom arising therefrom, comprising administering to a patient in need thereof or suspected of being in need thereof an isolated antibody or antigen-binding fragment thereof,
- wherein the antibody or antigen-binding fragment thereof specifically binds to a YFV protein, wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:307 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:459;
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:308 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:460;
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:311 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:463;
- (iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:320 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:471;
- or
- (v) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:341 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:492.
A method of treating or preventing a Yellow Fever Virus (YFV) infection or at least one symptom arising therefrom, comprising administering to a patient in need thereof or suspected of being in need thereof an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof,
- wherein the antibody or antigen-binding fragment thereof specifically binds to a YFV protein, wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:307 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:459;
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:308 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:460;
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:311 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:463;
- (iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:320 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:471;
- or
- (v) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:341 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:492.
A method of treating or preventing a Yellow Fever Virus (YFV) infection or at least one symptom arising therefrom, comprising administering to a patient in need thereof or suspected of being in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an isolated antibody or antigen-binding fragment thereof
- wherein the antibody or antigen-binding fragment thereof specifically binds to a YFV protein, wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:307 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:459;
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:308 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:460;
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:311 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:463;
- (iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:320 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:471;
- or
- (v) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:341 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:492.
A method of treating or preventing a Yellow Fever Virus (YFV) infection or at least one symptom arising therefrom, comprising administering to a patient in need thereof or suspected of being in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable excipient and an isolated nucleic acid encoding an antibody or antigen-binding fragment thereof
- wherein the antibody or antigen-binding fragment thereof specifically binds to a YFV protein, wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:307 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:459;
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:308 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:460;
- (iii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:311 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:463;
- (iv) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:320 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:471;
- or
- (v) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:341 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:492.
Dependencies are inferred from the claim text.